| Primary |
| Ovulation Induction |
28.6% |
| Pregnancy |
18.2% |
| In Vitro Fertilisation |
10.4% |
| Assisted Fertilisation |
7.8% |
| Drug Exposure During Pregnancy |
7.8% |
| Product Used For Unknown Indication |
5.2% |
| Cryptorchism |
3.9% |
| Infertility |
3.9% |
| Luteal Phase Deficiency |
2.6% |
| Weight Control |
2.6% |
| Drug Use For Unknown Indication |
1.3% |
| Hormone Replacement Therapy |
1.3% |
| Hypogonadism |
1.3% |
| Infertility Female |
1.3% |
| Management Of Reproduction |
1.3% |
| Oocyte Harvest |
1.3% |
| Weight Decreased |
1.3% |
|
| Drug Ineffective |
14.6% |
| Premature Baby |
14.6% |
| Ovarian Hyperstimulation Syndrome |
7.3% |
| Product Quality Issue |
7.3% |
| Blindness Congenital |
4.9% |
| Overdose |
4.9% |
| Petechiae |
4.9% |
| Pregnancy |
4.9% |
| Rash Pruritic |
4.9% |
| Twin Pregnancy |
4.9% |
| Venous Thrombosis |
4.9% |
| Adverse Event |
2.4% |
| Cerebral Infarction |
2.4% |
| Cerebral Venous Thrombosis |
2.4% |
| Congenital Anomaly |
2.4% |
| Drug Exposure Before Pregnancy |
2.4% |
| Drug Exposure During Pregnancy |
2.4% |
| Fontanelle Bulging |
2.4% |
| Haemoglobin Increased |
2.4% |
| Headache |
2.4% |
|
| Secondary |
| In Vitro Fertilisation |
33.5% |
| Ovulation Induction |
15.7% |
| Product Used For Unknown Indication |
14.4% |
| Ovarian Hyperstimulation Syndrome |
5.9% |
| Assisted Fertilisation |
4.2% |
| Infertility |
4.2% |
| Drug Exposure During Pregnancy |
3.4% |
| Blood Luteinising Hormone |
2.5% |
| Hypopituitarism |
2.5% |
| Polycystic Ovaries |
2.1% |
| Infertility Female |
1.7% |
| Luteal Phase Deficiency |
1.7% |
| Ovulation Disorder |
1.7% |
| Drug Use For Unknown Indication |
1.3% |
| Ill-defined Disorder |
1.3% |
| Cryptorchism |
0.8% |
| Prevention Of Premature Ovulation |
0.8% |
| Prophylaxis |
0.8% |
| Sedation |
0.8% |
| Anaesthesia |
0.4% |
|
| Melanoma Recurrent |
9.3% |
| Ovarian Hyperstimulation Syndrome |
7.4% |
| Spinal Fracture |
7.4% |
| Drug Exposure During Pregnancy |
5.6% |
| Maternal Exposure During Pregnancy |
5.6% |
| Metastases To Central Nervous System |
5.6% |
| Pelvic Pain |
5.6% |
| Twin Pregnancy |
5.6% |
| Vaginal Haemorrhage |
5.6% |
| Varicella |
5.6% |
| Benign Hydatidiform Mole |
3.7% |
| Ectopic Pregnancy |
3.7% |
| Foetal Exposure During Pregnancy |
3.7% |
| Metastases To Liver |
3.7% |
| Ovarian Torsion |
3.7% |
| Overdose |
3.7% |
| Pregnancy Test Positive |
3.7% |
| Pulmonary Embolism |
3.7% |
| Rash |
3.7% |
| Small For Dates Baby |
3.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
14.8% |
| Blood Thyroid Stimulating Hormone Decreased |
9.7% |
| In Vitro Fertilisation |
9.7% |
| Blood Corticotrophin Decreased |
7.4% |
| Blood Follicle Stimulating Hormone Decreased |
7.4% |
| Blood Luteinising Hormone Decreased |
7.4% |
| Growth Hormone Deficiency |
5.7% |
| Primary Hypothyroidism |
5.1% |
| Follicle-stimulating Hormone Deficiency |
4.5% |
| Luteinising Hormone Deficiency |
4.5% |
| Drug Use For Unknown Indication |
3.4% |
| Hypogonadism Male |
3.4% |
| Blood Antidiuretic Hormone Decreased |
2.8% |
| Hypopituitarism |
2.8% |
| Crohn's Disease |
2.3% |
| Ovarian Cyst |
2.3% |
| Hypogonadism |
1.7% |
| Infertility |
1.7% |
| Multifocal Motor Neuropathy |
1.7% |
| Vitamin B12 Deficiency |
1.7% |
|
| Gastroenteritis Viral |
14.0% |
| Pneumonia |
11.6% |
| Pulmonary Embolism |
11.6% |
| Obesity |
9.3% |
| Cholelithiasis |
7.0% |
| Drug Exposure During Pregnancy |
4.7% |
| Eye Disorder |
4.7% |
| Ovarian Hyperstimulation Syndrome |
4.7% |
| Unintended Pregnancy |
4.7% |
| Upper Limb Fracture |
4.7% |
| Uterine Haematoma |
4.7% |
| Acute Myeloid Leukaemia |
2.3% |
| Intra-uterine Death |
2.3% |
| Renal Dysplasia |
2.3% |
| Retained Products Of Conception |
2.3% |
| Ruptured Ectopic Pregnancy |
2.3% |
| Stillbirth |
2.3% |
| Twin Pregnancy |
2.3% |
| Vulvovaginal Pruritus |
2.3% |
|
| Interacting |
|
| Pulmonary Embolism |
100.0% |
|
